222 related articles for article (PubMed ID: 26039203)
1. Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update.
Arcese W; Picardi A; Santarone S; De Angelis G; Cerretti R; Cudillo L; Pennese E; Bavaro P; Olioso P; Dentamaro T; Cupelli L; Chierichini A; Ferrari A; Mengarelli A; Tirindelli MC; Testi M; Di Piazza F; Di Bartolomeo P;
Bone Marrow Transplant; 2015 Jun; 50 Suppl 2():S24-30. PubMed ID: 26039203
[TBL] [Abstract][Full Text] [Related]
2. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies.
Di Bartolomeo P; Santarone S; De Angelis G; Picardi A; Cudillo L; Cerretti R; Adorno G; Angelini S; Andreani M; De Felice L; Rapanotti MC; Sarmati L; Bavaro P; Papalinetti G; Di Nicola M; Papola F; Montanari M; Nagler A; Arcese W
Blood; 2013 Jan; 121(5):849-57. PubMed ID: 23165479
[TBL] [Abstract][Full Text] [Related]
3. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
[TBL] [Abstract][Full Text] [Related]
4. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
5. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
6. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.
Bacigalupo A; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Grasso R; Pozzi S; Colombo N; Tedone E; Varaldo R; Raiola AM
Bone Marrow Transplant; 2015 Jun; 50 Suppl 2():S37-9. PubMed ID: 26039205
[TBL] [Abstract][Full Text] [Related]
7. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Duléry R; Bastos J; Paviglianiti A; Malard F; Brissot E; Battipaglia G; Médiavilla C; Giannotti F; Banet A; de Wyngaert ZV; Ledraa T; Belhocine R; Sestili S; Adaeva R; Lapusan S; Isnard F; Legrand O; Vekhoff A; Rubio MT; Ruggeri A; Mohty M
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1407-1415. PubMed ID: 30871978
[TBL] [Abstract][Full Text] [Related]
8. [A clinical study of haploidentical transplantation using granulocyte colony-stimulating factor stimulating donor bone marrow].
Chen H; Ji S; Wang H
Zhonghua Nei Ke Za Zhi; 2001 Nov; 40(11):760-3. PubMed ID: 11930684
[TBL] [Abstract][Full Text] [Related]
9. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis.
Ogawa H; Ikegame K; Kaida K; Yoshihara S; Fujioka T; Taniguchi Y; Tamaki H; Inoue T; Hasei H; Iiboshi Y; Tazuke Y; Kawakami M; Kim EH; Soma T; Inoue T; Kawase I
Exp Hematol; 2008 Jan; 36(1):1-8. PubMed ID: 17920757
[TBL] [Abstract][Full Text] [Related]
10. Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients.
Tang BL; Zhu XY; Zheng CC; Liu HL; Geng LQ; Wang XB; Ding KY; Yao W; Tong J; Song KD; Zhang L; Qiang P; Sun ZM
Bone Marrow Transplant; 2015 Feb; 50(2):248-52. PubMed ID: 25365067
[TBL] [Abstract][Full Text] [Related]
11. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic bone marrow transplantation for chronic myeloid leukemia using HLA identical sibling donors primed with G-CSF.
Chen HR; Ji SQ; Wang HX; Yan HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):340-6. PubMed ID: 12513770
[TBL] [Abstract][Full Text] [Related]
13. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation: a multicenter randomized controlled study in southwest China.
Gao L; Wen Q; Chen X; Liu Y; Zhang C; Gao L; Kong P; Zhang Y; Li Y; Liu J; Wang Q; Su Y; Wang C; Wang S; Zeng Y; Sun A; Du X; Zeng D; Liu H; Peng X; Zhang X
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1932-9. PubMed ID: 25109850
[TBL] [Abstract][Full Text] [Related]
14. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
15. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
[TBL] [Abstract][Full Text] [Related]
17. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
[TBL] [Abstract][Full Text] [Related]
18. Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.
Peric Z; Mohty R; Bastos J; Brissot E; Battipaglia G; Belhocine R; Sestili S; Giannotti F; Vekhoff A; Ledraa T; Legrand O; Lapusan S; Isnard F; Labopin M; Bonnin A; Mediavilla C; Rubio MT; Ruggeri A; Duléry R; Malard F; Mohty M
Bone Marrow Transplant; 2020 Apr; 55(4):763-772. PubMed ID: 31673080
[TBL] [Abstract][Full Text] [Related]
19. Haploidentical, unmanipulated G-CSF-primed peripheral blood stem cell transplantation for high-risk hematologic malignancies: an update.
Huang WR; Li HH; Gao CJ; Bo J; Li F; Dou LP; Wang LL; Jing Y; Wang L; Liu DH; Yu L
Bone Marrow Transplant; 2016 Nov; 51(11):1464-1469. PubMed ID: 27322853
[TBL] [Abstract][Full Text] [Related]
20. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]